Novo mesto, Yugoslavia

Pavle Zupet

This inventor holds 2 USPTO granted patents. Top assignees: Krka, Krka, Tovarna Zdravil, N.sol.o.. Active years: 1987-1989.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 1987-1989

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Pavle Zupet: Innovator in Pharmaceutical Chemistry

Introduction

Pavle Zupet is a notable inventor based in Novo Mesto, YU. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of processes for synthesizing important compounds.

Latest Patents

Zupet holds two patents, both related to the preparation of 9-(2-hydroxyethoxymethyl)-guanine, commonly known as acyclovir. The first patent discloses a process for preparing this compound through the hydrolysis of a novel compound under basic conditions. The second patent also outlines a similar process, emphasizing the hydrolysis of the same compound but under mild basic conditions. These innovations are crucial for the pharmaceutical industry, particularly in the development of antiviral medications.

Career Highlights

Throughout his career, Zupet has worked with prominent companies such as Krka and Krka, Tovarna Zdravil, and N.sol.o. His experience in these organizations has allowed him to refine his skills and contribute to significant advancements in drug development.

Collaborations

Zupet has collaborated with notable coworkers, including Joze Kobe and Joze Gnidovec. These partnerships have likely enhanced his research and development efforts, leading to successful innovations in his field.

Conclusion

Pavle Zupet's work in the synthesis of acyclovir and his collaborations with esteemed colleagues highlight his valuable contributions to pharmaceutical chemistry. His patents represent important advancements that continue to impact the industry positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…